The Week

Bristol Myers Squibb (BMY) fell 0.91% this week to close at $63.06, while the S&P 500 slipped 0.08%, leaving the stock about 0.83 percentage points behind the benchmark. Trading was choppy: the stock opened Monday at $64.59, hit a weekly high of $65.29, then eased through midweek to a low of $62.19 on Thursday before a modest rebound into the close. Weekly amplitude came to 4.8%. Average daily volume of 15.1m shares ran roughly 56% above the 60-day median. The stock remains well below its 20-day average of $65.67 but above the 60-day average of $62.90.

Key Events

Company news centred on litigation, shareholder returns, and pipeline data. On 16 September, Bristol Myers filed suit against Amgen over its proposed Opdivo biosimilar. The same day the company declared a quarterly dividend of $0.63 per share. On 17 September it presented two-year data for its psoriatic arthritis pill, showing durable efficacy. Piper Sandler initiated coverage with a buy rating on 16 September. The company also scheduled its third-quarter results for 29 October before the open. Industry-side commentary during the week covered the bispecifics pipeline outlook and valuation grades for healthcare names.

Analyst Ratings

Across 29 covering institutions, 7 rate the stock buy, 3 overweight, 17 hold, 1 underweight, 1 sell, and 1 has no opinion. That leaves 10 firms at buy or overweight. The consensus rating is buy, with a consensus target of $66.71, about 5.8% above the latest price. Targets range from $40 to $82, a wide spread that reflects meaningful disagreement on valuation. Within the pharmaceutical industry, Bristol Myers ranks 2nd out of 204 names on the ratings leaderboard.

The Week Ahead

The main company event ahead is the Q3 2026 earnings release on 29 October before the open, with estimates pointing to EPS of $1.46 and revenue of $12.7b. On the macro side, traders can track the Richmond Fed composite index on 22 September, EIA crude and Cushing inventories on 23 September, and initial jobless claims, the current account balance, and new home sales on 24 September.

In Short

This week pitted a supportive analyst backdrop against softer price action. Consensus remains buy with a target above spot, and the valuation sits at a modest 13.9x P/E with a 3.98% dividend yield. Yet the stock lagged the S&P 500, the latest session showed large-lot money tilting toward the sell side, and the target range is unusually wide. The next test is whether the late-October earnings update can hold up against that split in expectations.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.